NYX — Nyctalopin

The NYX gene provides instructions for making a protein called nyctalopin, which is essential for normal vision. Nyctalopin is located in the retina, the light-sensitive tissue at the back of the eye. Its main job is to help pass visual signals from the light-detecting cells (photoreceptors) to the next set of cells in the visual pathway (bipolar cells). You can think of nyctalopin as a crucial bridge or connector that ensures the message of 'light' is successfully transmitted from the eye to the brain. When there is a mutation or change in the NYX gene, the nyctalopin protein may be missing, too short, or not work correctly. As a result, the bridge is broken, and the visual signals, especially those for seeing in low light, cannot be passed along properly. This leads to a condition called X-linked complete congenital stationary night blindness (CSNB). People with this condition have difficulty seeing in the dark or in dim light from birth. They also typically have other vision problems, such as severe nearsightedness (myopia), reduced sharpness of vision, and involuntary eye movements (nystagmus). Importantly, 'stationary' means that while these vision problems are present from birth, they do not get worse over time. The NYX gene is located on the X chromosome, which means the condition is inherited in an X-linked recessive pattern. Because males have only one X chromosome, a single mutated copy of the gene is enough to cause the disorder. Females have two X chromosomes, so they would need mutations in both copies to be affected, which is rare. Therefore, this condition primarily affects males, while females with one mutated copy are usually carriers who do not have symptoms but can pass the gene to their children. Families affected by this condition can work with genetic counselors to understand the inheritance pattern and the risks for future generations.

Gene description: The NYX gene encodes nyctalopin, a leucine-rich repeat protein involved in the synaptic transmission within the retina.

Patient and family guide: The NYX gene provides instructions for making a protein called nyctalopin, which is essential for normal vision. Nyctalopin is located in the retina, the light-sensitive tissue at the back of the eye. Its main job is to help pass visual signals from the light-detecting cells (photoreceptors) to the next set of cells in the visual pathway (bipolar cells). You can think of nyctalopin as a crucial bridge or connector that ensures the message of 'light' is successfully transmitted from the eye to the brain. When there is a mutation or change in the NYX gene, the nyctalopin protein may be missing, too short, or not work correctly. As a result, the bridge is broken, and the visual signals, especially those for seeing in low light, cannot be passed along properly. This leads to a condition called X-linked complete congenital stationary night blindness (CSNB). People with this condition have difficulty seeing in the dark or in dim light from birth. They also typically have other vision problems, such as severe nearsightedness (myopia), reduced sharpness of vision, and involuntary eye movements (nystagmus). Importantly, 'stationary' means that while these vision problems are present from birth, they do not get worse over time. The NYX gene is located on the X chromosome, which means the condition is inherited in an X-linked recessive pattern. Because males have only one X chromosome, a single mutated copy of the gene is enough to cause the disorder. Females have two X chromosomes, so they would need mutations in both copies to be affected, which is rare. Therefore, this condition primarily affects males, while females with one mutated copy are usually carriers who do not have symptoms but can pass the gene to their children. Families affected by this condition can work with genetic counselors to understand the inheritance pattern and the risks for future generations.

Gene function: Nyctalopin, encoded by NYX, is a crucial component of the ON-bipolar cell pathway in the retina. It is involved in the signal transduction from photoreceptors to bipolar cells, specifically mediating the ON-response to light. Dysfunction of nyctalopin disrupts this critical synaptic transmission, leading to impaired night vision and progressive vision loss.

Protein structure: The NYX gene encodes a protein known as nyctalopin, which consists of 481 amino acids. Nyctalopin is a member of the small leucine-rich proteoglycan (SLRP) superfamily. Its structure is characterized by a central region containing 11 tandem leucine-rich repeats (LRRs), which are flanked by characteristic cysteine-rich motifs at both the N-terminal (LRRNT) and C-terminal (LRRCT) ends. These LRR domains are typically involved in mediating protein-protein interactions, suggesting that nyctalopin acts as a scaffold or binding partner for other molecules at the cell surface. Nyctalopin is an extracellular protein that is tethered to the cell membrane. It possesses an N-terminal signal peptide that directs it to the endoplasmic reticulum for secretion, and a C-terminal hydrophobic region that serves as a signal for the attachment of a glycosylphosphatidylinositol (GPI) anchor. This GPI anchor secures the protein to the outer leaflet of the cell membrane, specifically at the dendritic tips of depolarizing bipolar cells in the retina. The proper folding of the LRR domains and the correct attachment of the GPI anchor are essential for nyctalopin's stability and its ability to function in the retinal synaptic complex.

Molecular function: The NYX gene encodes a protein called nyctalopin, which is a member of the small leucine-rich proteoglycan (SLRP) family. Nyctalopin is an extracellular, membrane-anchored protein characterized by a central domain containing multiple leucine-rich repeats (LRRs) flanked by cysteine-rich regions. It is tethered to the cell membrane via a glycosylphosphatidylinositol (GPI) anchor at its C-terminus. The LRR domains are known to mediate protein-protein interactions, suggesting that nyctalopin functions as a structural or organizing molecule at the cell surface. In the retina, nyctalopin plays a critical and specific role in the transmission of visual signals from photoreceptors (rods and cones) to depolarizing (ON) bipolar cells. It is localized to the dendritic tips of ON bipolar cells, precisely at the ribbon synapses where these cells receive input from photoreceptors. Nyctalopin is essential for the proper assembly and function of the macromolecular signaling complex at these synapses. Specifically, it is required for the correct subcellular localization and function of TRPM1, the transient receptor potential cation channel that mediates the light-evoked depolarization of ON bipolar cells. When light strikes the photoreceptors, it reduces their release of the neurotransmitter glutamate. In the dark, glutamate binds to mGluR6 receptors on ON bipolar cells, keeping the TRPM1 channels closed. The light-induced decrease in glutamate relieves this inhibition, allowing TRPM1 channels to open and depolarize the bipolar cell. Nyctalopin acts as a crucial scaffold or auxiliary subunit in this process, ensuring that TRPM1 and other necessary components are correctly positioned and functionally coupled to the mGluR6 signaling cascade. Without functional nyctalopin, this signaling pathway is disrupted, leading to a failure of signal transmission to the inner retina and the clinical manifestation of night blindness.

Expression pattern: The NYX gene exhibits a highly specific expression pattern, primarily localized to the retina and the kidney. Within the retina, NYX expression is crucial for the proper functioning of the visual pathway. Studies have shown that the NYX transcript and its encoded protein, nyctalopin, are expressed in several key retinal cell types, including photoreceptors (both rods and cones), bipolar cells, amacrine cells, and ganglion cells. At the cellular level, nyctalopin is specifically localized to the tips of the dendrites of depolarizing (ON) bipolar cells. These dendrites invaginate into the synaptic terminals of photoreceptors, forming specialized structures known as ribbon synapses. The precise localization of nyctalopin at these synaptic sites is essential for its role in mediating the transmission of visual signals from the photoreceptors to the inner retina. The protein is predicted to be tethered to the extracellular surface of the bipolar cell membrane via a glycosylphosphatidylinositol (GPI) anchor, positioning it to interact with other synaptic proteins.

Mutation spectrum: The mutation spectrum of the NYX gene is diverse, encompassing a wide range of variant types that lead to congenital stationary night blindness (CSNB1A). Over 90 pathogenic variants have been reported in the Human Gene Mutation Database (HGMD) and ClinVar. These include missense mutations, which change a single amino acid and often disrupt the structure or function of the leucine-rich repeat (LRR) domains; nonsense mutations and frameshift deletions/insertions, which lead to premature truncation and loss of the protein; and splice-site mutations that alter normal mRNA processing. While mutations are distributed throughout the gene, many cluster within the LRR domains, highlighting the importance of these regions for nyctalopin's function in protein-protein interactions. Large genomic deletions encompassing part or all of the NYX gene have also been identified in some families. Notably, a specific 24-base pair in-frame deletion (c.85_108del) has been identified as a founder mutation in several families of American descent, suggesting a common ancestral origin for this particular variant. The variety of mutation types underscores the critical need for the full, intact nyctalopin protein for normal retinal synaptic transmission.

Pathogenic variants: 1. c.85_108del (p.Arg29_Ala36del): A 24-base pair in-frame deletion that removes eight amino acids from the N-terminal cysteine cluster. This is a known founder mutation in families of American descent and causes classic complete CSNB (CSNB1A). 2. c.1049G>A (p.Trp350Ter): A nonsense mutation that introduces a premature stop codon, predicted to eliminate the C-terminal portion of the protein required for the GPI anchor, likely resulting in a non-functional, soluble protein and causing CSNB1A. 3. c.105C>A (p.Cys35Ter): Another nonsense mutation leading to early protein truncation and loss of function, associated with the complete form of CSNB. 4. c.560C>A (p.Ala187Lys): A missense mutation located within the leucine-rich repeat domains, likely disrupting protein folding or interactions, found in Swedish families with CSNB1A. 5. c.281G>C (p.Arg94Pro): A missense mutation in the second leucine-rich repeat, identified in Chinese families, demonstrating the importance of this specific residue for nyctalopin function in retinal signaling.

Clinical significance: Mutations in the NYX gene are the primary cause of X-linked complete congenital stationary night blindness (CSNB1A). This non-progressive retinal disorder is characterized by a constellation of visual impairments that are present from birth. The hallmark symptom is nyctalopia, or difficulty seeing in low-light conditions, due to the complete absence of rod pathway function. In addition to night blindness, affected individuals typically present with reduced visual acuity, severe nearsightedness (high myopia), involuntary eye movements (nystagmus), and misalignment of the eyes (strabismus). The severity of these symptoms can vary among patients, but the condition itself does not worsen over time. The clinical diagnosis of CSNB1A is strongly supported by specific findings on electroretinography (ERG). Patients exhibit a 'negative' ERG, characterized by a normal a-wave (reflecting intact photoreceptor function) but a severely reduced or absent b-wave (indicating a failure of signal transmission to the inner retina). Specifically, in the complete form of CSNB caused by NYX mutations, there is a complete loss of rod-mediated b-wave responses, while cone-mediated responses are only mildly affected. This electrophysiological profile distinguishes CSNB1A from other forms of night blindness and retinal dystrophies. Interestingly, some mutations in the NYX gene have been associated with high myopia in the absence of the other classic features of CSNB1A, such as night blindness or a negative ERG. This suggests that nyctalopin may have independent roles in refractive development and retinal signaling, and that certain missense mutations may selectively disrupt its function in eye growth while preserving its role in synaptic transmission.

Inheritance: X-linked Recessive

Chromosomal location: Xp11.4

Genotype-phenotype correlations: Genotype-phenotype correlations in NYX-related disorders are complex. The vast majority of pathogenic variants in the NYX gene, including deletions, nonsense mutations, and many missense mutations, lead to the classic phenotype of X-linked complete congenital stationary night blindness (CSNB1A). These mutations typically result in a loss of functional nyctalopin, either through premature truncation of the protein or by disrupting its proper folding, localization, or interaction with other synaptic components. The resulting complete loss of rod pathway signaling manifests as the characteristic night blindness and negative ERG. However, some specific missense mutations in the NYX gene have been linked to a different clinical presentation: high myopia without night blindness or the typical ERG abnormalities of CSNB. This suggests that certain amino acid substitutions may selectively impair nyctalopin's role in regulating eye growth and refractive development while leaving its function in retinal synaptic transmission relatively intact. This divergence in phenotypes highlights the multifaceted role of nyctalopin in the eye and indicates that the specific nature and location of the mutation within the protein can significantly influence the resulting clinical features.

Research and therapeutic approaches: Currently, there are no FDA-approved treatments or cures for congenital stationary night blindness (CSNB) caused by mutations in the NYX gene. Management of the condition is primarily supportive and focuses on addressing the associated visual symptoms. This includes the prescription of corrective lenses (glasses or contact lenses) to manage the severe myopia that is commonly present. For patients with significant night blindness, practical strategies such as using adequate lighting and avoiding driving in low-light conditions are recommended. Regular ophthalmological evaluations are important to monitor visual acuity and manage any complications like strabismus. However, significant progress is being made in the realm of investigational therapies, particularly gene therapy. The successful use of gene therapy to treat other inherited retinal diseases, such as the approval of Luxturna (voretigene neparvovec-rzyl) for RPE65-mediated inherited retinal disease, has spurred interest in similar approaches for CSNB. Proof-of-concept studies in the 'nob' mouse model of NYX-CSNB have been highly encouraging. Researchers have demonstrated that delivering a functional copy of the Nyx gene specifically to retinal bipolar cells using viral vectors can restore the expression of nyctalopin, rescue the ERG b-wave, and improve visual function in these mice. While these gene therapy approaches are still in the preclinical stages for NYX and have not yet entered human clinical trials, they represent a promising pipeline strategy for potentially restoring synaptic transmission and treating the underlying cause of the disease in the future.

Diagnostic testing: The diagnosis of NYX-related congenital stationary night blindness (CSNB1A) typically begins with a comprehensive clinical eye examination, including visual acuity testing, refraction, and assessment of eye movements. The definitive clinical test is the electroretinogram (ERG), which reveals the characteristic 'negative' waveform with a normal a-wave and an absent or severely reduced b-wave under scotopic (dark-adapted) conditions. This finding points to a defect in signal transmission from photoreceptors to bipolar cells. Molecular genetic testing is used to confirm the diagnosis and identify the specific pathogenic variant in the NYX gene. This is often performed using targeted gene panels that include NYX and other genes associated with CSNB and inherited retinal diseases. Whole exome or whole genome sequencing may also be employed, particularly if panel testing is uninformative. Genetic counseling is crucial for affected individuals and their families, as CSNB1A follows an X-linked recessive inheritance pattern. This means that males are predominantly affected, while females are typically asymptomatic carriers, although rare cases of manifesting female carriers due to skewed X-chromosome inactivation have been reported. Counseling helps families understand the inheritance risks and the non-progressive nature of the condition.

Animal models: The most significant animal model for studying the NYX gene is the naturally occurring mouse mutant known as 'nob' (no b-wave). The nob phenotype is caused by an 85-bp deletion in the mouse Nyx gene, which encodes the nyctalopin protein. This deletion results in a frameshift and premature truncation of the protein. The nob mouse exhibits a functional phenotype that closely mimics human complete congenital stationary night blindness (CSNB1A), including the characteristic absence of the electroretinogram (ERG) b-wave and abnormal spontaneous activity in the inner retina. Behavioral testing of nob mice has demonstrated a significant decrease in visual sensitivity, confirming their utility as a model for the human disease. Studies using the nob mouse model have been instrumental in elucidating the function of nyctalopin. They have shown that nyctalopin expression on the dendrites of depolarizing bipolar cells (DBCs) is required for normal synaptic transmission from photoreceptors to these second-order neurons. In the absence of functional nyctalopin, DBCs fail to respond to light-induced changes in photoreceptor neurotransmitter release, leading to the loss of the ERG b-wave. Furthermore, gene therapy experiments in nob mice, where nyctalopin expression was restored specifically in retinal bipolar cells, successfully rescued the ERG b-wave and restored visual function, providing proof-of-concept for potential therapeutic interventions in humans.

Population genetics: Congenital stationary night blindness (CSNB) is a rare disorder, and the specific carrier frequency for NYX gene mutations in the general population is low. Because it is an X-linked recessive condition, the disease primarily manifests in males, while females are typically asymptomatic carriers. The prevalence of CSNB as a whole is estimated to be roughly 1 in 30,000 to 1 in 50,000, with NYX mutations accounting for a significant proportion of the complete form (CSNB1A). While specific carrier frequencies for NYX mutations are not as well-defined as for more common recessive disorders, data from large population databases like gnomAD indicate that pathogenic variants in this gene are exceedingly rare globally. However, founder effects can lead to higher frequencies in specific populations; for example, a 24-bp deletion (c.85_108del) has been identified as a founder mutation in several American families, indicating a shared ancestral origin and a localized increase in prevalence within that specific lineage.

Selected references: 1. Bech-Hansen NT, et al. Mutations in NYX, encoding the leucine-rich proteoglycan nyctalopin, cause X-linked complete congenital stationary night blindness. Nat Genet. 2000;26(3):319-23. PMID: 11062471 2. Pusch CM, et al. The complete form of X-linked congenital stationary night blindness is caused by mutations in a gene encoding a leucine-rich repeat protein. Nat Genet. 2000;26(3):324-7. PMID: 11062472 3. Gregg RG, et al. Identification of the gene and the mutation responsible for the mouse nob phenotype. Invest Ophthalmol Vis Sci. 2003;44(1):378-84. PMID: 12506099 4. Zeitz C, et al. Congenital stationary night blindness: an analysis and update of genotype-phenotype correlations and pathogenic mechanisms. Prog Retin Eye Res. 2015;45:58-110. PMID: 25324231 5. Gregg RG, et al. Nyctalopin expression in retinal bipolar cells restores visual function in a mouse model of complete X-linked congenital stationary night blindness. J Neurophysiol. 2007;98(5):3023-33. PMID: 17881478 6. Zhang Q, et al. Mutations in NYX of individuals with high myopia, but without night blindness. Mol Vis. 2007;13:330-6. PMID: 17392683 7. Allen LE, et al. Genotype-phenotype correlation in British families with X linked congenital stationary night blindness. Br J Ophthalmol. 2003;87(11):1413-20. PMID: 14609846